Alnylam Pharmaceuticals Inc

ALNY: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|K$LOCK|>>Q#lLOCK|&?!TR>

Alnylam Earnings: Strong Launch of Amvuttra for ATTR-CM Boosts 2025 Outlook

Alnylam generated second-quarter net product revenue of $672 million, a 64% increase compared with the prior-year period. Management raised its guidance for its TTR franchise by 34% at the midpoint, and investors sent the stock up 15% on July 31.

Sponsor Center